Bone Material Properties in Trabecular Bone From Human Iliac Crest Biopsies After 3- and 5-Year Treatment With Risedronate
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Long-term effects of risedronate on bone mineral maturity/crystallinity and collagen cross-link ratio in triple iliac crest biopsies of osteoporotic women were evaluated. In this double-blinded study, 3- and 5-year treatment with risedronate arrested the tissue aging encountered in untreated osteoporosis and in osteoporosis treated with other antiresorptives. This effect may be contributing to risedronate's antifracture efficacy. Introduction: Risedronate is widely used in the treatment of osteoporosis. It reduces bone turnover, increases BMD, and decreases fracture risk. To date, there are no data available on the long-term effects of risedronate on bone material properties in humans. Materials and Methods: Osteoporotic women enrolled in the VERT-NA trial received either risedronate (5 mg/day, orally) or placebo for up to 5 years. All subjects received calcium. They also received vitamin D supplementation if deficient at baseline. Triple iliac crest biopsies were collected from a subset of these subjects at baseline, 3 years, and 5 years. Mineral maturity/crystallinity and collagen cross-link ratio was measured in these biopsies using Fourier transform infrared imaging. Results: Patients that received placebo exhibited increased mineral maturity/crystallinity and collagen cross-link ratio after 3 and 5 years compared with baseline values. On the contrary, patients that received risedronate retained baseline values in both bone material indices throughout. A more spatially detailed analysis revealed that this was achieved mainly through beneficial effects on active bone-forming areas. Surprisingly, patients that received risedronate achieved premenopausal values at bone-forming areas in both indices after 5 years of treatment. Conclusion: Long-term treatment with risedronate affects bone material properties (mineral maturity/crystallinity and collagen cross-link ratio) and arrests the tissue aging apparent in untreated osteoporosis. These changes at the material level of the bone matrix may contribute to risedronate's rapid and sustained antifracture efficacy in osteoporotic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Materials become insensitive to flaws at nanoscale: Lessons from nature
Gao, H., Ji, B., Jäger, I. L., Arzt, E., & Fratzl, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0631609100 · Cited by 1,922 · cited 3×
“Based on such studies, models for the importance of mineral crystallite shape and size in determining bone strength have been put forth.((1,35,36)) The effect”
BackgroundMethodSelf-citationProtein secondary structures in water from second-derivative amide I infrared spectra
Dong, A., Huang, P., & Caughey, W. S. (1990) · Biochemistry · doi:10.1021/bi00465a022 · Cited by 1,333
Nancollas, G. H., Tang, R., Phipps, R. J., Henneman, Z., Gulde, S., Wu, W., Mangood, A., Russell, R. G. G., & Ebetino, F. H. (2006) · Bone · doi:10.1016/j.bone.2005.05.003 · Cited by 862
Self-citation
Cited by
Shane, E., Burr, D., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., Dempster, D. W., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1998 · Cited by 2,147
Self-citationRussell, R. G. G., Watts, N. B., Ebetino, F. H., & Rogers, M. J. (2008) · Osteoporosis International · doi:10.1007/s00198-007-0540-8 · Cited by 1,411
Shane, E., Burr, D., Ebeling, P. R., Abrahamsen, B., Adler, R. A., Brown, T. D., Cheung, A. M., Cosman, F., Curtis, J. R., Dell, R., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.253 · Cited by 1,116
Self-citationSaito, M., & Marumo, K. (2010) · Osteoporosis International · doi:10.1007/s00198-009-1066-z · Cited by 906
Bone mineralization density distribution in health and disease
Roschger, P., Paschalis, E. P., Fratzl, P., & Klaushofer, K. (2008) · Bone · doi:10.1016/j.bone.2007.10.021 · Cited by 648
Self-citationBone composition: relationship to bone fragility and antiosteoporotic drug effects
Boskey, A. L. (2013) · BoneKEy Reports · doi:10.1038/bonekey.2013.181 · Cited by 424
Bisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Self-citationOhtori, S., Inoue, G., Orita, S., Yamauchi, K., Eguchi, Y., Ochiai, N., Kishida, S., Kuniyoshi, K., Aoki, Y., Nakamura, J., et al. (2013) · Spine · doi:10.1097/brs.0b013e31828826dd · Cited by 293
Rizzoli, R., Åkesson, K., Bouxsein, M., Kanis, J. A., Napoli, N., Papapoulos, S., Reginster, J.-Y., & Cooper, C. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1453-5 · Cited by 249
“Bisphosphonate use may negatively affect collagen by preventing or reducing its maturation [82], although this finding has not been consistently replicated [83].”
Infrared Assessment of Bone Quality: A Review
Paschalis, E. P., Mendelsohn, R., & Boskey, A. L. (2011) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-010-1751-4 · Cited by 215
“in evaluating various therapeutic protocols, providing insight into the mechanisms by which the various drugs work and therefore assisting in the design of new and more targeted ones [7, 13, 17, 22, 26, 49, 52, 55, 56, 58, 62, 71].”
Self-citationTowards the in vivo prediction of fragility fractures with Raman spectroscopy
Buckley, K., Kerns, J. G., Vinton, J., Gikas, P. D., Smith, C., Parker, A. W., Matousek, P., & Goodship, A. E. (2015) · Journal of Raman Spectroscopy · doi:10.1002/jrs.4706 · Cited by 68
Metadata
- Authors
- Durchschlag, E., Paschalis, E. P., Zoehrer, R., Roschger, P., Fratzl, P., Recker, R., Phipps, R., & Klaushofer, K.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-10-01
- Volume
- 21
- Issue
- 10
- Pages
- 1581-1590
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W2065667561
- Cited by
- 119
- References
- 5
- FWCI
- 8.62
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.